Figure 2. Primary outcome (A), the bilateral endoscopic nasal polyp score at 20 weeks treatment is significantly lower compared to baseline in benralizumab group (P=0.004) but not placebo (P=0.166). (B) Similarly, CT polyp score is lower in the benralizumab group (P=0.012) but not placebo (P=0.233).
The reduction in polyp size and CT score were not uniform among all subjects treated with benralizumab. The benralizumab treated group ranged from no improvement to a three-point reduction in total bilateral endoscopic polyp score. CT score reduction was likewise variable among the benralizumab treated group. Figure 3, shows the endoscopic image and sinus CT scan of two representative patients that improved with benralizumab treatment.